Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 88.82M | 79.70M | 60.11M | 89.30M | 39.31M | 54.64M |
Gross Profit | 43.91M | 38.70M | -11.68M | 26.21M | -10.68M | 6.64M |
EBITDA | -15.07M | -19.42M | -104.29M | -7.82M | -73.04M | -11.14M |
Net Income | -9.76M | -20.99M | -108.35M | -11.38M | -74.74M | -7.77M |
Balance Sheet | ||||||
Total Assets | 69.59M | 66.75M | 65.60M | 125.94M | 105.92M | 161.51M |
Cash, Cash Equivalents and Short-Term Investments | 17.24M | 17.52M | 26.05M | 16.31M | 27.88M | 26.03M |
Total Debt | 6.35M | 7.00M | 4.41M | 4.92M | 4.16M | 4.59M |
Total Liabilities | 30.90M | 29.88M | 23.92M | 37.73M | 18.90M | 29.61M |
Stockholders Equity | 38.69M | 36.87M | 41.68M | 88.21M | 87.02M | 131.90M |
Cash Flow | ||||||
Free Cash Flow | -14.73M | -26.52M | -46.74M | -9.93M | -23.24M | -22.14M |
Operating Cash Flow | -14.58M | -26.33M | -46.49M | -9.37M | -22.63M | -21.92M |
Investing Cash Flow | -169.76K | -189.82K | -4.25M | -1.56M | -5.60M | -8.70M |
Financing Cash Flow | 4.08M | 17.99M | 60.48M | -643.21K | 30.09M | 33.35M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
64 Neutral | €15.34B | 13.05 | -4.03% | 3.83% | -1.58% | -101.37% | |
60 Neutral | AU$91.85M | 20.30 | 6.80% | 2.73% | 15.48% | 135.65% | |
60 Neutral | AU$91.85M | 20.30 | 6.80% | 2.73% | 15.48% | 135.65% | |
49 Neutral | AU$23.38M | ― | -33.40% | ― | -13.09% | -139.06% | |
49 Neutral | AU$23.38M | ― | -33.40% | ― | -13.09% | -139.06% | |
48 Neutral | AU$160.76M | ― | -21.85% | ― | 30.54% | 88.42% | |
45 Neutral | AU$23.47M | ― | -47.74% | ― | 43.14% | 51.35% | |
45 Neutral | AU$23.47M | ― | -47.74% | ― | 43.14% | 51.35% | |
43 Neutral | AU$31.87M | ― | ― | 4.22% | -199.40% | ||
43 Neutral | AU$31.87M | ― | ― | 4.22% | -199.40% | ||
41 Neutral | AU$31.22M | ― | -23.00% | ― | -2.14% | 11.40% | |
41 Neutral | AU$31.22M | ― | -23.00% | ― | -2.14% | 11.40% |
Bubs Australia Ltd. announced the issuance of over 10 million unquoted securities as part of an employee incentive scheme, set to vest in June 2027. This move is likely aimed at aligning employee interests with long-term company performance, potentially impacting the company’s operational strategy and market positioning by fostering a motivated workforce.
The most recent analyst rating on (AU:BUB) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. has submitted its New Infant Formula Submission to the US FDA, marking a crucial step towards securing permanent regulatory approval in the US market. This move is part of Bubs’ strategy to solidify its position in the US, its largest market, and is expected to enhance its growth prospects. The successful completion of a large-scale clinical trial in the US underscores Bubs’ technical and operational capabilities, positioning it as a credible global manufacturer in the dairy industry.
The most recent analyst rating on (AU:BUB) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. announced a favorable outcome in a legal dispute involving its subsidiary, The Infant Food Co. Pty Limited, against Alice Trading Limited and Willis Trading Limited, subsidiaries of Alpha Professional Holdings Ltd. The Australian Centre for International Commercial Arbitration awarded Bubs a total of $26.5 million for debt, breach of contract, and damages claims. This outcome strengthens Bubs’ financial position and underscores its ability to successfully navigate complex legal challenges, potentially enhancing its standing in the industry.
Bubs Australia Limited reported a positive operating cash flow for the second consecutive quarter, with a notable improvement in financial performance for Q3 FY25. The company achieved a group net revenue of $23.2 million, a 52.6% increase from the previous corresponding period, and a significant reduction in EBITDA loss. Bubs is making progress in the USA market, with strong sales growth on platforms like Amazon and in physical stores, partly due to competitors’ supply shortages. The company is also advancing its clinical trials in the USA, aiming for FDA approval later in the year, which could further enhance its market positioning.